1. Volume 64, Issue 6, Pages 895-902 (December 2013)
A New Risk Classification System for Therapeutic Decision Making with Intermediate- risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy 
Zachary S. Zumsteg, Daniel E. Spratt, Isaac Pei, Zhigang Zhang, Yoshiya Yamada, Marisa Kollmeier, Michael J. Zelefsky 
European Urology 
Volume 64, Issue 6, Pages (December 2013)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
A comparison of favorable versus unfavorable intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy showing significant differences in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) local failure, (c) distant metastasis (DM), and (d) prostate cancer–specific mortality (PCSM).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

3. Fig. 2
Outcomes with no unfavorable risk factors (RFs), one unfavorable RF, or two or three unfavorable RFs (ie, Gleason 4+3=7, ≥50% of biopsy cores with cancer, or more than one intermediate risk factor): (a) prostate-specific antigen (PSA) recurrence-free survival, (b) local failure, (c) distant metastasis (DM), and (d) prostate cancer–specific mortality (PCSM).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

4. Supplementary Fig. 1
– A comparison of low-risk and favorable intermediate-risk (IR) prostate cancer patients undergoing dose-escalated external-beam radiation therapy showing no significant difference in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) distant metastasis (DM), and (c) prostate cancer–specific mortality (PCSM).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

5. Supplementary Fig. 2
– Prostate cancer–specific mortality (PCSM) in (a) favorable or (b) unfavorable intermediate-risk prostate cancer with and without neoadjuvant and concurrent androgen-deprivation therapy (ADT).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

6. Supplementary Fig. 3
– A comparison of high-risk and intermediate-risk (IR) patients with two or three unfavorable risk factors (URFs) undergoing dose-escalated external-beam radiation therapy showing no significant difference in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) distant metastasis (DM), and (c) prostate cancer–specific mortality (PCSM).
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions